Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology PluvictoⓇ - Radioligand therapy target PSMA NCT04689828 PSMAfore (CAAA617B12302) References Abbreviations Other PluvictoⓇ - Radioligand therapy target PSMA NCT04720157 PSMAddition (CAAA617C12301) Metastatic hormone sensitive prostate cancer Phase 3 1126 Radiographic Progression Free Survival (rPFS) Indication Metastatic castration-resistant prostate cancer, pre-taxane Indication Phase Phase 3 Phase Patients 450 Patients Primary Radiographic Progression Free Survival (rPFS) Primary Outcome Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Arm 1: Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used Arm 2: For participants randomized to the ARDT arm, the change of ARDT treatment will be administered per the physician's orders. Best supportive care, including ADT may be used mCRPC patients that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or MHSPC settings Primary Analysis: 2022 Final Analysis: 2025 Publication TBD Measures Arms Intervention Target Patients Arm 1: 177Lu-PSMA-617 Participant will receive 7.4 GBq (+/- 10%) 177Lu- PSMA-617, once every 6 weeks for a planned 6 cycles, in addition to the Standard of Care (SOC); ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Arm 2: For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order Patients with metastatic Hormone Sensitive Prostate Cancer (mHSPC) Read-out Milestone(s) Publication Primary Analysis: 2024 TBD 74 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation